Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Solventum (SOLV) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.This health care company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 13.24%.For the last reported quarter, S ...

Core Viewpoint - Progressive (PGR) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with a consensus outlook suggesting a positive earnings picture that could influence its stock price in the near term [1][3]. Earnings Expectations - The consensus EPS estimate for Progressive is $4.60 per share, reflecting a year-over-year increase of +23.3% [3]. - Expected revenues for the quarter are $20.38 billion, which is a 19.3% increase from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 0.49% higher, indicating a collective reassessment by covering analysts [4]. - The Most Accurate Estimate for Progressive is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +4.31% [10][11]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - Stocks with this combination have historically produced a positive surprise nearly 70% of the time [8]. Historical Performance - In the last reported quarter, Progressive exceeded the expected earnings of $3.43 per share by delivering $4.08, resulting in a surprise of +18.95% [12]. - The company has beaten consensus EPS estimates in all of the last four quarters [13]. Conclusion - Progressive is positioned as a compelling candidate for an earnings beat, but investors should consider other factors that may influence stock performance beyond earnings results [16].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Walgreens Boots Alliance (WBA) despite an increase in revenues, with actual results being crucial for stock price movement [1][3]. Earnings Expectations - The expected quarterly earnings per share (EPS) for Walgreens is $0.53, reflecting a year-over-year decrease of 55.8% [3]. - Revenues are projected to reach $37.92 billion, which is a 2.4% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.82% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - A positive Earnings ESP of +9.39% suggests that analysts are optimistic about Walgreens' earnings prospects [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - Walgreens currently holds a Zacks Rank of 2, enhancing the likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Walgreens exceeded the expected EPS of $0.37 by delivering $0.51, resulting in a surprise of +37.84% [12]. - Over the past four quarters, Walgreens has beaten consensus EPS estimates three times [13]. Conclusion - While Walgreens is positioned as a compelling earnings-beat candidate, other factors should also be considered when evaluating the stock ahead of its earnings release [16].

Core Viewpoint - Nike (NKE) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ended February 2025, with the actual results having a significant impact on its near-term stock price [1][2]. Earnings Expectations - The consensus estimate for Nike's quarterly earnings is $0.28 per share, reflecting a year-over-year decrease of 71.4% [3]. - Expected revenues are projected to be $11.12 billion, down 10.6% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2.45% higher in the last 30 days, indicating a reassessment by analysts [4]. - A positive Earnings ESP reading is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank of 1, 2, or 3 [8]. Earnings Surprise Prediction - The Most Accurate Estimate for Nike is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.90%, suggesting a bearish outlook from analysts [10][11]. - Despite a Zacks Rank of 3, the combination of a negative Earnings ESP makes it challenging to predict an earnings beat [11]. Historical Performance - In the last reported quarter, Nike was expected to post earnings of $0.63 per share but actually delivered $0.78, resulting in a surprise of +23.81% [12]. - Over the past four quarters, Nike has consistently beaten consensus EPS estimates [13]. Conclusion - While an earnings beat or miss may influence stock movement, other factors can also play a significant role in stock performance [14]. - Nike does not currently appear to be a compelling earnings-beat candidate, and investors should consider additional factors before making investment decisions [16].

Core Viewpoint - Vermilion Energy (VET) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ended December 2024, with actual results potentially impacting its near-term stock price [1][3]. Earnings Expectations - The consensus estimate for Vermilion's quarterly earnings is $0.36 per share, reflecting a year-over-year decrease of 62.1%. Revenues are projected to be $358.35 million, down 6.7% from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 171.43% higher, indicating a reassessment by analysts regarding the company's earnings prospects [4][10]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +19.44%, suggesting that analysts have recently become more optimistic about Vermilion's earnings [10][11]. Historical Performance - In the last reported quarter, Vermilion was expected to post earnings of $0.33 per share but only achieved $0.24, resulting in a surprise of -27.27%. Over the last four quarters, the company has only beaten consensus EPS estimates once [12][13]. Investment Considerations - While Vermilion is seen as a compelling earnings-beat candidate, investors are advised to consider other factors that may influence stock performance beyond just earnings results [14][16].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Marvell Technology, driven by higher revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - Marvell is expected to report quarterly earnings of $0.59 per share, reflecting a year-over-year increase of +28.3% [3]. - Revenues are projected to reach $1.8 billion, which is a 26.5% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - A positive Earnings ESP of +2.77% suggests that analysts have recently become more optimistic about Marvell's earnings prospects [10]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - Marvell currently holds a Zacks Rank of 2, indicating a high likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Marvell exceeded the expected earnings of $0.40 per share by delivering $0.43, resulting in a surprise of +7.50% [12]. - Over the past four quarters, Marvell has beaten consensus EPS estimates three times [13]. Conclusion - While an earnings beat is a positive indicator, other factors may also influence stock movement, making it essential to consider the broader context [14][16]. - Marvell is viewed as a compelling candidate for an earnings beat, but investors should remain aware of additional influencing factors [16].